TUMOR DEVELOPMENT RESEARCH

cell-bullet4.jpg La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid leukemia.  Lymphoma and leukemia are cancers of the blood.

"PLC-beta 3 is an enzyme, but the function we found was a completely different function that no one knew it had  -- as a tumor suppressor," said the La Jolla Institute's Toshiaki  Kawakami, M.D., Ph.D., who led the research team.  The study, conducted in animal models, could eventually lead to the development of new therapies directed towards controlling this newly discovered cellular mechanism.  Read the Full Story

faculty appointments
how to help
news
  • 1/23/2012 - La Jolla Institute Scientist Takes Quest to Conquer Type 1 Diabetes to the Next Level
    Learn More
  • 1/12/2012 - La Jolla Institute Researchers Identify Pivotal Immune Cell in Type 1 Diabetes in Humans
    Learn More
  • 12/24/2011 -  San Diego Union-Tribune Top 5 San Diego Science Stories of 2011 | La Jolla Institute Highlighted in Stem Cell Central
    Article link | .pdf
upcoming seminars
  • Maki Nakayama, "Insulin TcR transgenic mice and TcR and diabetes penetrance" Wednesday 08/17/11: 12:00 PM
  • Casey Weaver, "Sequential Actions of Innate and Adaptive Immune Cells in Intestinal Antibacterial Defense: A Shared Role for IL-22" Thursday 08/25/11: 12:00 PM
  • More Seminars
fact-amer-cancer-soc.gif